Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 10th Preview)
-
FDA rejection of Replimune melanoma therapy
The FDA again rejected Replimune’s oncolytic virus therapy for advanced melanoma after the company failed to resolve trial-related doubts, according to the agency’s renewed decision. Replimune previously received a refusal in July and returned for a reconsideration, with regulators maintaining concerns about the evidence supporting the program. The setback adds to a broader reassessment inside the FDA over the amount and type of clinical data needed to clear next-generation biologics programs. Replimune’s engineered virus is designed to activate antitumor immunity, but the agency’s repeated rejection signals that the path to approval remains contingent on strengthening the clinical package. For investors and competitors, the action underscores how FDA expectations for oncolytic viral and immuno-oncology platforms may be tightening, particularly where endpoint interpretation and trial design questions persist.
-
Gilead and Kymera deepen molecular-glue degrader pipeline
Gilead exercised its option to exclusively license KT-200, a preclinical oral CDK2 molecular-glue degrader developed by Kymera Therapeutics. The move follows an earlier June 2025 option and comes as CDK2-targeting strategies expand amid setbacks and uneven performance from first-wave approaches in the clinic. Kymera characterized KT-200 as a selective degrader of CDK2 designed to reduce toxicity risks seen with broader cell-cycle kinase inhibition. Gilead plans IND-enabling work, positioning KT-200 for potential human testing next year. Separately, the broader protein-degrader push is extending across major oncology pipelines, including new collaborations that blend degrader payloads with antibody targeting to improve therapeutic windows.
-
China NMPA approval for MGI’s DNBSeq-T1+ sequencer
MGI Tech said its DNBSeq-T1+ sequencer received medical device registration from China’s NMPA, enabling deployment in the Chinese clinical market. The benchtop instrument targets applications including cancer diagnostics, rare disease testing, and genetic screening. The platform can generate up to 1.2 terabases of data per day across two flow cells, completing a paired-end 150 bp run in about 24 hours. MGI said the balance of speed, throughput, and footprint is designed to be “clinical application friendly.” The regulatory clearance strengthens competition in China’s sequencing-instrument market as more platform vendors seek clinical workflows beyond research use, while also supporting the scaling of genomics-based testing capacity in routine care.
-
Pre-IPO funding for Oricell’s solid-tumor CAR-T push
Oricell Therapeutics secured a pre-IPO venture financing worth more than $110 million to advance CAR-T programs aimed at solid tumors. The company’s lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T program being developed for advanced hepatocellular carcinoma. Oricell said Ori-C101 has completed early human testing across three dose levels in a 10-patient study, reporting an objective response at the highest dose and a disease-control signal. The funding is also intended to support a broader set of next-generation cell-therapy modalities, including additional CAR-T programs and in vivo approaches. The financing arrives as the company positions for capital-market milestones and expands a strategy tailored to the antigen heterogeneity and immunosuppressive microenvironments that complicate solid-tumor cell therapy.
-
Avalyn Pharma targets IPO to fund Phase 3 inhaled IPF programs
Avalyn Pharma filed to pursue an IPO to fund Phase 3 trials for inhaled respiratory therapies for idiopathic pulmonary fibrosis. The biotech’s lead program, AP01, is an inhaled formulation of pirfenidone that is in a Phase 2b study (NCT06329401), with plans to move into Phase 3 using expected IPO proceeds. The company also is advancing AP02, an inhaled form of nintedanib, and AP03, a preclinical inhaled combination of pirfenidone plus nintedanib designed to address additive side-effect limitations seen with oral co-administration. Avalyn said it had $138 million in cash at the start of 2026 and employs 51 full-time staff. For the sector, the filing reflects continued market appetite for late-stage reformulations of established drugs—especially where inhalation may improve tolerability and targeting compared with existing oral dosing regimens.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.